- Home
- ATEX vs KOD Comparison
ATEX vs KOD Comparison
Compare ATEX & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- KOD
- Stock Information
- Founded
- ATEX 1997
- KOD 2009
- Country
- ATEX United States
- KOD United States
- Employees
- ATEX N/A
- KOD N/A
- Industry
- ATEX Telecommunications Equipment
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATEX Telecommunications
- KOD Health Care
- Exchange
- ATEX Nasdaq
- KOD Nasdaq
- Market Cap
- ATEX 555.0M
- KOD 454.7M
- IPO Year
- ATEX N/A
- KOD 2018
- Fundamental
- Price
- ATEX $37.35
- KOD $3.45
- Analyst Decision
- ATEX Buy
- KOD Hold
- Analyst Count
- ATEX 2
- KOD 4
- Target Price
- ATEX $64.00
- KOD $8.00
- AVG Volume (30 Days)
- ATEX 242.6K
- KOD 306.7K
- Earning Date
- ATEX 02-11-2025
- KOD 03-27-2025
- Dividend Yield
- ATEX N/A
- KOD N/A
- EPS Growth
- ATEX N/A
- KOD N/A
- EPS
- ATEX N/A
- KOD N/A
- Revenue
- ATEX $5,902,000.00
- KOD N/A
- Revenue This Year
- ATEX $49.39
- KOD N/A
- Revenue Next Year
- ATEX $2.84
- KOD N/A
- P/E Ratio
- ATEX N/A
- KOD N/A
- Revenue Growth
- ATEX 66.77
- KOD N/A
- 52 Week Low
- ATEX $27.37
- KOD $2.19
- 52 Week High
- ATEX $42.91
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ATEX 53.11
- KOD 28.84
- Support Level
- ATEX $36.50
- KOD $3.59
- Resistance Level
- ATEX $38.95
- KOD $3.89
- Average True Range (ATR)
- ATEX 1.39
- KOD 0.35
- MACD
- ATEX -0.48
- KOD 0.07
- Stochastic Oscillator
- ATEX 27.24
- KOD 4.98
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.